The hepatic cytochrome P450 reductase null mouse as a tool to identify a successful candidate entity

Toxicology Letters

Volumn 162, Issue 1 SPEC. ISS., 2006, Pages 111-117

  Henderson, Colin J ^a   Pass, Georgia J ^a   Wolf, C Roland ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

P450; Pharmacokinetics; Reductase; Toxicokinetics; Transgenic

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; ANTINEOPLASTIC AGENT; BILE ACID; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 REDUCTASE; DICLOFENAC; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; ISOENZYME; LIPID; LIVER ENZYME; MITOXANTRONE; NAVELBINE; PACLITAXEL; PARACETAMOL; TAMOXIFEN; VINBLASTINE; VINCRISTINE; XENOBIOTIC AGENT;

ACUTE LEUKEMIA; ARTICLE; BLADDER CANCER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; BREEDING; CARDIOTOXICITY; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME REGULATION; GENE DELETION; HOMEOSTASIS; HUMAN; IN VIVO STUDY; KIDNEY CLEARANCE; LETHALITY; LIVER METABOLISM; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MOUSE STRAIN; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; SARCOMA; SOLID TUMOR; TESTIS CANCER; TOXICOKINETICS;

EID: 32644436021     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2005.10.016     Document Type: Article

References (31)

1. Arlt, V.M., Henderson, C.J. Bioactivation of 3-aminobenzanthrone, a human metabolite of the environmental pollutant 3-nitrobenzanthrone: evidence for DNA adduct formation mediated by cytochrome P450 enzymes and peroxidases, Cancer Lett., in press.
2. V.M. Arlt, M. Stiborova, C.J. Henderson, M.R. Osborne, C.A. Bieler, E. Frei, V. Martinek, B. Sopko, C.R. Wolf, H.H. Schmeiser, and D.H. Philips Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols Cancer Res. 65 2005 2644 2652
3. P. Baldrick Toxicokinetics in preclinical evaluation Drug Discov. Today 8 2003 127 133
4. A. Bartoszek Metabolic activation of adriamycin by NADPH-cytochrome P450 reductase; overview of its biological and biochemical effects Acta Biochim. Pol. 49 2002 323 331
5. A. Bartoszek, and C.R. Wolf Enhancement of doxorubicin toxicity following activation by NADPH cytochrome P450 reductase Biochem. Pharmacol. 43 1992 1449 1457
6. K. Bergman, L. Muller, and S.M. Teigen Series: current issues in mutagenesis and carcinogenesis. No. 65. The genotoxicity and carcinogenicity of paracetamol: a regulatory (re)view Mutat. Res. 349 1996 263 288
7. A.V. Boddy, and S.M. Yule Metabolism and pharmacokinetics of oxazaphosphorines Clin. Pharmacokinet. 38 2000 291 304
8. A. Bodo, E. Bakos, F. Szeri, A. Varadi, and B. Sarkadi The role of multidrug transporters in drug availability, metabolism and toxicity Toxicol. Lett. 140-141 2003 133 143
9. J.T. Buters, S. Sakai, T. Richter, T. Pineau, D.L. Alexander, U. Savas, J. Doehmer, J.M. Ward, C.R. Jefcoate, and F.J. Gonzales Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas Proc. Natl. Acad. Sci. U.S.A. 96 1999 1977 1982
10. D.C. Dahlin, G.T. Miwa, A.Y. Lu, and S.D. Nelson N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen Proc. Natl. Acad. Sci. U.S.A. 81 1984 1327 1331
11. T.P. Dalton, M.Z. Dieter, R.S. matlib, N.L. Childs, H.G. Shertzer, M.B. Genter, and D.L. Nebert Targeted knockout of Cyp1a1 gene does not alter hepatic constitutive expression of other genes in the mouse [Ah] battery Biochem. Biophys. Res. Commun. 267 2000 184 189
12. R. Dixit, J. Riviere, K. Krishman, and M.E. Andersen Toxicokinetics and physiologically based toxicokinetics in toxicology and risk assessment J. Toxicol. Environ. Health B Crit. Rev. 6 2003 1 40
13. M. Faber, C. Coudray, H. Hida, M. Mousseau, and A. Favier Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study Biol. Trace Elem. Res. 47 1995 117 123
14. R.A. Fleming An overview of cyclophosphamide and ifosfamide pharmacology Pharmacotherapy 17 1997 146S 154S
15. C.J. Henderson, D.M. Otto, D. Carrie, M.A. Magnuson, A.W. McLaren, I. Rosewell, and C.R. Wolf Inactivation of the hepatic cytochrome P450 system by conditional deletion of hepatic cytochrome P450 reductase J. Biol. Chem. 278 2003 13480 13486
16. C.J. Henderson, D.M. Otto, A.W. McLaren, D. Carrie, and C.R. Wolf Knockout mice in xenobiotic metabolism Drug Metab. Rev. 35 2003 385 392
17. C.J. Henderson, and C.R. Wolf Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology Mol. Interv. 3 2003 331 343
18. S. Ishibashi, and M. Schwarz Disruption of cholesterol 7alpha-hydroxylase gene in mice. I. Postnatal lethality reversed by bile acid and vitamin supplementation J. Biol. Chem. 271 1996 18017 18023
19. S.S. Lee, J.T. Buters, T. Pineau, P. Fernandez-Salguero, and F.J. Gonzales Role of CYP2E1 in the hepatotoxicity of acetaminophen J. Biol. Chem. 271 1996 12063 12067
20. D.W. Nebert, and D.W. Russell Clinical importance of the cytochromes P450 Lancet 360 2002 1155 1162
21. D.R. Nelson, D.C. Zeldin, S.M. Hoffman, L.J. Maltais, H.M. Wain, and D.L. Nebert Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants Pharmacogenetics 14 2004 1 18
22. D.M. Otto, C.J. Henderson, D. Carrie, M. Davey, T.E. Gundersen, R. Blomhoff, R.H. Adams, C. Tickle, and C.R. Wolf Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis Mol. Cell. Biol. 23 2003 6103 6116
23. G.J. Pass, D. Carrie, M. Boylan, S. Lorimore, E. Wright, B. Houston, C.J. Henderson, and C.R. Wolf Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse Cancer Res. 65 2005 4211 4217
24. C.J. Patten, P.E. Thomas, R.L. Guy, M. Lee, F.J. Gonzales, F.P. Guengerich, and C.S. Yang Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics Chem. Res. Toxicol. 6 1993 511 518
25. J.L. Raucy, J.M. Lasker, C.S. Lieber, and M. Black Acetaminophen activation by human liver cytochromes P450IIE1 and P4501A2 Arch. Biochem. Biophys. 271 1989 270 283
26. D.S. Riddick, C. Lee, S. Ramji, E.C. Chinje, R.L. Cowen, K.J. Williams, A.V. Patterson, I.J. Stratford, C.S. Morrow, A.J. Townsend, Y. Jonaidi, C.S. Chen, T. Su, H. Lu, P.S. Schwartz, and D.J. Waxman Cancer chemotherapy and drug metabolism Drug Metab. Dispos. 33 2005 1083 1096
27. M. Schwarz, E.G. Lund, K.D. Setchell, H.J. Kayden, J.E. Zerwekh, I. Bjorkhem, J. Herz, and D.W. Russell Disruption of cholesterol 7alpha-hydroxylase gene in mice. II. Bile acid deficiency is overcome by induction of oxysterol 7alpha-hydroxylase J. Biol. Chem. 271 1996 18024 18031
28. P.K. Singal, N. Siveski-Iliskovic, M. Hill, T.P. Thomas, and T. Li Combination therapy with probucol prevents adriamycin-induced cardiomyopathy J. Mol. Cell. Cardiol. 27 1995 1055 1063
29. G. Voelcker, T. Wagner, C. Wientzek, and H.J. Hohorst Pharmacokinetics of "activated" cyclophosphamide and therapeutic efficacies Cancer 54 Suppl. 6 1984 1179 1186
30. X.J. Wang, M.P. Chamberlain, O. Vassieva, C.J. Henderson, and C.R. Wolf Relationship between hepatic phenotype and changes in gene expression in the cytochrome P450 reductase (POR) null mice Biochem. J 2005
31. S.M. Yule, L. Price, M. Cole, A.D. Pearson, and A.V. Boddy Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion Cancer Chemother. Pharmacol. 47 2001 222 228